Tiziana Life Sciences, Ltd (TLSA), a biotechnology company developing its lead development candidate, intranasal foralumab, Monday announced that it is withdrawing its proposed public offering of common shares due to market conditions.
In pre-market activity, TLSA shares were trading at $1.85, up 3.93% on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.